20 Countries with the Highest Rates of Stomach Cancer in the World

Published on April 25, 2024 at 8:53 am by Laiba Immad in Lists, News

In this article, we will be taking a look at the 20 countries with the highest rates of stomach cancer in the world. If you do not want to learn about the global cancer trends, head straight to the 5 Countries with the Highest Rates of Stomach Cancer in the World.

Overview of the Global Stomach Cancer Treatment Market

The global stomach cancer treatment market was valued at $2.61 billion in 2018 and is expected to reach $20.92 billion by 2032, with a noteworthy compounding annual growth rate (CAGR) of 16% over the forecast period. With over a million cases reported globally in 2020, stomach cancer is the fourth leading cause of cancer death with approximately 800,000 deaths in the same year.

With 26,890 new instances of stomach cancer expected to be reported in 2024 in the US, stomach cancer is a major public health concern in the United States. Growth in the stomach cancer treatment market in North America is anticipated due to the high incidence of stomach cancer in the US and developments in treatment methods such as targeted and immunotherapies.

The drug type, disease indication, administration route, drug class, and distribution channel are some of the characteristics that divide the stomach cancer therapy market. Due to the emphasis on treating these particular illness indications, gastric cancer, and the gastroesophageal junction cancer sector notably retained the biggest market share of 85.47% in 2021.

In the global market for stomach cancer treatments, Novartis AG, Pfizer Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Bristol Myers Squibb Company are some of the major companies propelling innovation and development.

Global Cancer Trends and Financial Impacts on Patients

The worldwide oncology market, valued at $208 billion in 2022, grew with the inclusion of cancer prevention, diagnosis, and treatment. Reports indicate a strong rise in the market at a CAGR of 12% between 2022 and 2032, resulting in a $628 billion market value at the end of the projection period.

The pharmaceutical sector is an important sector that invests more than $50 billion a year in oncology research and development, demonstrating its unrelenting commitment to the fight against cancer. Immuno-oncology (IO) is also a major force behind the industry pipeline, accounting for about 40% of oncology’s yearly R&D expenditure. This substantial investment demonstrates the industry’s commitment to using immunotherapies to transform the way that cancer is treated and improve patient outcomes.

Although the United States has seen a significant 29% decrease in cancer-related mortality since 1991, mostly due to a rise in the use of cancer medications, Europe offers an advantageous market, as both the number of cancer diagnoses and deaths are rising there. On the other hand, cancer patients all over the world bear heavy financial burdens; the median yearly costs range from $1,730 to $4,727, and they are roughly $976 to $1,170 higher than those of non-cancer patients. Between 22% and 64% of cancer patients experience financial difficulty, which makes them more stressed about their medical expenditures. Low-income and uninsured people are more affected.

Leading Players in the Global Cancer Care Market

Talking about cancer care, certain companies stand out for their innovations and acknowledgeable contributions to the cancer care market. These companies include Illumina, Inc. (NASDAQ:ILMN), BeiGene. Ltd. (NASDAQ:BGNE), and Bristol Meyers Squibb, among others.

In the field of cancer treatment, Illumina, Inc. (NASDAQ:ILMN) is a market leader, particularly in stomach cancer. One of their many offerings is the TruSight Oncology 500 Assay, which can identify many sorts of variants from low-quality samples, including microsatellite instability (MSI) and tumor mutational burden (TMB). Furthermore, the TruSight Oncology UMI Reagents lower error rates for identifying low-frequency variations, and their TruSight Tumor 170 assay concurrently targets DNA and RNA variants.

Products from Illumina, Inc. (NASDAQ:ILMN) helped support zolbetuximab, a monoclonal antibody that targets CLDN18.2 in stomach cancer, in a critical international phase 3 trial. Because of the FDA’s priority consideration of this trial, zolbetuximab may become the first-ever approved targeted treatment for advanced stomach or gastroesophageal junction cancer. Despite a 2% decline from the previous fiscal year, Illumina, Inc. (NASDAQ:ILMN) recorded sales of about $1,115 million in Q4 2023, a 3% rise over Q4 2022, which brings the total revenue for the fiscal year 2023 to $4,497 million. With 79 NovaSeq X instruments shipped in Q4 2023 and 352 instruments shipped for the entire fiscal year 2023, instrument shipments continued to be robust. Illumina also intends to exit GRAIL by the end of Q2 2024, a hint of a major strategic change in the company’s operations.

On the other hand, BeiGene. Ltd. (NASDAQ:BGNE) has also created effective cancer treatments, such as the BTK inhibitor zanubrutinib and the checkpoint inhibitor tislelizumab, which are effective in treating a variety of malignancies, including stomach cancer. A major step toward the development of potent cancer treatments was reached in 2024 when sales of its BTK inhibitor Brukinsa crossed $1.3 billion worldwide.

To develop and promote tislelizumab in significant markets, BeiGene. Ltd. (NASDAQ:BGNE) has grown internationally and formed alliances with companies like Novartis. Novartis has returned all rights to BeiGene for tislelizumab, giving them complete control over the drug’s development and commercialization. In terms of finances, BeiGene. Ltd. (NASDAQ:BGNE)’s sales increased significantly, hitting $2.459 billion in 2023. Nonetheless, net losses of $1.21 billion for 2023 and $882 million for 2022 were declared.

A scientist in a lab researching the biology of a cancer cell.

Our Methodology

For Our methodology, we have ranked the countries with the highest rates of stomach cancer in the world based on the stomach cancer prevalence rates per 100,000 people in 2020. Since the data for stomach cancer rates per 100,000 people were separately available for both men and women, we combined the data for both of the genders for a combined stomach cancer rate per 100,000 people. For countries that did not have their women prevalence rates for stomach cancer available, we randomly picked 4 countries which had the rates per 100,000 people available for both men and women and then divided the women’s rates with men’s for these 4 countries. After that we added all these 4 answers together and divided them by the total number of answers. The resulting number was taken as the sample average and was then multiplied by the men’s rates for the countries whose women rates were missing. For the accuracy of data, we relied on NIH.

Here is our list of the 20 countries with the highest rates of stomach cancer in the world.

20. Mozambique

Cancer Rate per 100,000 People: 1.41

Stomach cancer is a major concern in Mozambique, particularly for the elderly. It’s interesting to note that as women age, they appear to be more susceptible to mortality from it than men. Mozambique reported around 25,446 new cases and over 18,014 fatalities from stomach cancer in just 2020.

19. Indonesia

Cancer Rate per 100,000 People: 2.7

Stomach cancer accounted for 2,821 fatalities in Indonesia or 0.17% of all deaths, in 2020. The country ranks 19th among the countries with the highest rate of stomach cancer in the world with an age-adjusted death rate from stomach cancer of 1.28 per 100,000 people. Indonesia spent around $486.9 million in 2016 treating over a million cancer cases, including stomach cancer.

18. Lesotho

Cancer Rate per 100,000 People: 2.96

Lesotho has some of the world’s highest stomach cancer incidence and mortality rates. In 2020, around 2.9 per 100,000 people were affected, with men being 2 to 3 times more likely to suffer from it compared to women. People older than 50 were the most affected.

17. Burkina Faso

Cancer Rate per 100,000 People: 3.94

Burkina Faso has higher than average rates of stomach cancer incidence and mortality worldwide. There were very few facilities (around 2) offering cancer treatment treatments in Burkina Faso as of 2019. In 2018, Burkina Faso saw 8.3% of total stomach cancer deaths.

16. Eritrea

Cancer Rate per 100,000 People: 4.08

Eritrea saw 18.8 cases per annum of colorectal cancer between 2011-2017, which is a relatively low reported incidence. The male-to-female ratio among the patients stood at 1:1.61, with an average age of 57.62 years. Interestingly, around half of the patients were younger than 50 which suggests that more research is necessary.

15. Kuwait

Cancer Rate per 100,000 People: 4.08

The age-adjusted incidence rate of stomach cancer in Kuwait is comparatively low, coming in at 4.08 per 100,000 for both men and women between 1998 and 2004. Kuwait also has one of the lowest age-standardized disability-adjusted life years (DALY) rates for stomach cancer (64.9 per 100,000 people) among the nations analyzed in 2019.

14. Ethiopia

Cancer Rate per 100,000 People: 4.37

Stomach cancer was the primary cause of cancer-related mortality in Ethiopia especially in Addis Ababa, accounting for 131 deaths (13.6%) between 2007 and 2017, placing Ethiopia among countries with the highest rates of stomach cancer in the world. Men and women are affected equally by this burden, with stomach cancer having higher death rates than liver and breast cancer.

13. Sudan

Cancer Rate per 100,000 People: 4.9

In Sudan, cancer accounts for 5% of all fatalities and is the third most common cause of death in the country. According to a study that looked at nearly 33,000 cancer cases in Sudan between 2009-2013, chronic myeloid leukemia and lymphoma were the most common hematological cancers in the country, but stomach cancer stood out as one of the most common solid tumors. 52% of cancer patients were between the ages of 15-54, while 7.2% were older than 55.

12. Saudi Arabia

Cancer Rate per 100,000 People: 5.2

Around 4,066 instances of stomach cancer were reported in Saudi Arabia between 2004 and 2017, making up roughly 3.7% of all cancer cases in the country. Jazan had the lowest rates of stomach cancer, whereas Riyadh, Najran, and the Eastern region had the highest ASIRs. There were an average of 23 cases of stomach cancer each year among Saudi women, with the majority of cases occurring in those 75 years of age and older. In Saudi Arabia, the death rate from stomach cancer was 2.05% for women and 3.29% for males, making KSA stand among the countries with high rates of stomach cancer.

11. Nigeria

Cancer Rate per 100,000 People: 5.6

Nigeria has a high prevalence rate of gastric cancer that makes up 3.5% of all cancers in male Nigerians and accounts for 3% of cancer-related deaths in the country. Research on the epidemiological and histological characteristics of primary gastrointestinal tract malignancies in Nigeria has shown how common gastric cancer is, accounting for 15.6% cancer cases, which is more than expected. Furthermore, a study found that there are 17 incidences of stomach cancer in the area per year.

10. Democratic Republic of Korea

Cancer Rate per 100,000 People 32.28

Stomach cancer was the most frequent cancer type in the Democratic Republic of Korea (DPRK), from 1999 to 2018, accounting for 28,078 new cases in 2008 that mostly affected men. The presence of Helicobacter pylori infection is one of the key risk factors, along with smoking and eating behaviors. Stomach cancer ranks fourth among cancer-related deaths in the country, with 4,346 fatalities reported due to stomach cancer in 2020.

9. Belarus

Cancer Rate per 100,000 People: 33.84

Stomach cancer poses a serious threat to public health in Belarus. The country had the highest age-standardized rate of stomach cancer in 2020 with 33.8 cases per 100,000 people.

8. Kazakhstan

Cancer Rate per 100,000 People: 34.68

Kazakhstan’s gastric cancer mortality rate is still a major cause for concern although the cases have seen a decrease. Gastric cancer caused 19,672 fatalities between 2009-2018, with a mean death age of 67.8 years. Trends show that death rates are falling for those under 30 but rising for those in the 70–74 age range. With a decreasing trend over time, the average annual standardized death rate was 13.2 per 100,000 population.

7. Iran

Cancer Rate per 100,000 People: 34.9

The cancer rate per 100,000 people in Iran if 34.9. The prognosis for patients over 70 is poorer than that of patients under 50, with a 1.67-fold increased relative chance of death. With a comparatively poor overall 5-year survival rate of 12.8%, gastric cancer is also the top cause of cancer-related fatalities in Iran, accounting for 16.1% of all cancer-related deaths.

6. China

Cancer Rate per 100,000 People: 41.8

China is the sixth country with the largest incidence of stomach cancer cases globally, accounting for 478,000 cases in 2020. In China, stomach cancer has a substantial financial impact with the the average direct cost per patient estimated at US $9,899, primarily for medical costs. For 79.2% of families, out-of-pocket costs for newly diagnosed patients represent a significant amount of household income, causing financial distress. With 373,789 fatalities from cancer in 2020, stomach cancer is China’s third most common cause of cancer-related deaths.

Click here to continue reading the 5 Countries with the Highest Rates of Stomach Cancer in the World.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up